DURHAM, N.C. --(BUSINESS WIRE)--Sep. 21, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, today announced that it is executing its succession plan for its long-serving Chairman and CEO and that effective September 17, 2021 , Vicente Anido , PhD.
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 20, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and
AR-15512 (0.003%) BID Advancing to Phase 3; No Treatment-Related Serious or Systemic Adverse Events Reported Conference Call and Webcast Today, September 15 th , at 5:00 p.m. ET DURHAM, N.C. --(BUSINESS WIRE)--Sep. 15, 2021-- Aerie Pharmaceuticals, Inc.
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 13, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and
